« Previous Next » Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 2 , Pages 141-151 , March 2006

Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model

Benjamin K. Canales, M.D., M.P.H.
- Department of Urology, University of Minnesota, Minneapolis, MN 55455, USA
Yingming Li, M.D.
- Department of Urology, University of Minnesota, Minneapolis, MN 55455, USA
Melissa G. Thompson, B.A.
- Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Joseph M. Gleason, M.S.
- Department of Urology, University of Minnesota, Minneapolis, MN 55455, USA
Zhi Chen, Ph.D.
- Department of Pharmacology and Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Bahaa Malaeb, M.D.
- Department of Urology, University of Minnesota, Minneapolis, MN 55455, USA
David R. Corey, Ph.D.
- Department of Pharmacology and Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Brittney-Shea Herbert, Ph.D.
- Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
- Indiana University Cancer Center and Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
Jerry W. Shay, Ph.D.
- Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Kenneth S. Koeneman, M.D.
- Department of Urology, University of Minnesota, Minneapolis, MN 55455, USA
- Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
- Center for Prostate Cancer, University of Minnesota, Minneapolis, MN 55455, USA
- Corresponding author. Tel.: +1-612-626-0964.

To access this article, please choose from the options below

☆ This work was supported by a New Award Idea, Department of Defense, CDMRP, DAMD 17-01-1-0107 “Targeting Osteoblastic Bone Metastasis with a Novel Site Restricted Gene Therapy” and Department of Defense, CDMRP, DAMD17-02-1-0148 “Targeting Orthotopic and Osseous Prostate Cancer Xenografts with Selective, Systemic Telomerase Inhibition” (K.S.K.), and a subcontract to DOD Consortium Award, DAMD17-03-2-0033 to Emory University (P.I. Jonathan Simmons).

Isis Corporation and Geron Corporation provided small molecule, oligonucleotide-based telomerase template inhibitors used in this study.

PII: S1078-1439(05)00264-4

doi: 10.1016/j.urolonc.2005.11.003

« Previous Next » Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 2 , Pages 141-151 , March 2006